Is LYRA's Q4 2024 EPS growth sustainable?

**Lyra Therapeutics' Q4 2024 EPS growth is not currently sustainable**. Here's why:

1. **Financial Performance Challenges**: Lyra Therapeutics reported a net loss of $93.4 million for the year ended December 31, 2024. This significant loss indicates that the company is not profitable at the moment, making discussions of EPS growth irrelevant in the context of its financial health.
2. **Workforce Reduction and Cost-Cutting Measures**: The company has implemented cost-cutting measures, including a 75% reduction in its workforce, to conserve capital. Such measures are indicative of financial strain and suggest that the company is focused on survival rather than sustainable growth at this time.
3. **Ongoing Clinical Trials and Uncertain Outcomes**: Lyra's primary product candidate, LYR-210, has not met its primary endpoint in the Phase 3 ENLIGHTEN 1 trial. The company is continuing with the ENLIGHTEN 2 trial, but the outcome is uncertain. The pause in development for LYR-220 due to cost-saving measures also indicates uncertainty in the company's future revenue streams.
4. **Stock Price and Market Capitalization**: The company's stock price has reached a 52-week low, with a market capitalization shrinking to $10.7 million. This decline reflects investor sentiment and could impact the company's ability to raise capital for future growth.

In conclusion, Lyra Therapeutics is facing significant financial challenges, and its Q4 2024 EPS growth (if applicable) is not a reliable indicator of the company's current sustainability. The company's focus is likely on addressing its immediate financial needs and the outcomes of its clinical trials rather than sustainable EPS growth.